According to the World Health Organization classification of MPNs, the primary MF, polycythemia vera (PV), and essential thrombocythemia (ET) are grouped as the Janus kinase 2 (JAK2) MPNs, with genetic mutations playing a distinctive role in their pathophysiology [3–5]. Here, JAK2 is linked to essential thrombocythemia.